- Home
- OFS vs GNTA Comparison
OFS vs GNTA Comparison
Compare OFS & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- GNTA
- Stock Information
- Founded
- OFS 2001
- GNTA 2014
- Country
- OFS United States
- GNTA Italy
- Employees
- OFS N/A
- GNTA N/A
- Industry
- OFS Finance/Investors Services
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OFS Finance
- GNTA Health Care
- Exchange
- OFS Nasdaq
- GNTA Nasdaq
- Market Cap
- OFS 108.5M
- GNTA 75.9M
- IPO Year
- OFS 2012
- GNTA 2021
- Fundamental
- Price
- OFS $8.10
- GNTA $3.81
- Analyst Decision
- OFS
- GNTA Strong Buy
- Analyst Count
- OFS 0
- GNTA 1
- Target Price
- OFS N/A
- GNTA $25.00
- AVG Volume (30 Days)
- OFS 31.1K
- GNTA 10.9K
- Earning Date
- OFS 03-03-2025
- GNTA 01-01-0001
- Dividend Yield
- OFS 16.80%
- GNTA N/A
- EPS Growth
- OFS N/A
- GNTA N/A
- EPS
- OFS N/A
- GNTA N/A
- Revenue
- OFS $49,799,000.00
- GNTA N/A
- Revenue This Year
- OFS N/A
- GNTA N/A
- Revenue Next Year
- OFS N/A
- GNTA N/A
- P/E Ratio
- OFS N/A
- GNTA N/A
- Revenue Growth
- OFS N/A
- GNTA N/A
- 52 Week Low
- OFS $7.75
- GNTA $2.20
- 52 Week High
- OFS $11.94
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- OFS 50.99
- GNTA 39.48
- Support Level
- OFS $7.92
- GNTA $3.52
- Resistance Level
- OFS $8.17
- GNTA $4.50
- Average True Range (ATR)
- OFS 0.10
- GNTA 0.34
- MACD
- OFS 0.01
- GNTA -0.02
- Stochastic Oscillator
- OFS 84.00
- GNTA 24.37
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.